Sabby Management Portfolio holdings

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, down 24% from $3.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $999M in Q1 2015, closing 85 positions and reducing 66 holdings. Its most notable exit was Pfizer, an estimated $42.1M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, down from 90% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Sabby Management opened a new position in Tempest Therapeutics worth $4.69M.

• Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
• Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
• Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
• Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
• Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
• Sabby Management opened 126 new positions and closed 85 in Q1 2015.
• Sabby Management's portfolio value fell 24% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.